Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

View Full Paper
Ask AI
Bookmark
Share

Authors

CHCyrille HulinCCCarolyne CroizierPLPascal Lenain

Discussion

Loading...

Member takes

Overview

Prospective study reveals efficacy and safety of teclistamab in relapsed refractory multiple myeloma patients, suggesting real-world application.

Key Points

  • To evaluate the real-world effectiveness and safety of teclistamab in patients with triple-class exposed relapsed refractory multiple myeloma.
  • Multicenter, observational prospective study by Intergroupe Francophone du Myelome (IFM 2023-01)
  • Included patients with confirmed RRMM who received teclistamab
  • Primary objective measured overall response rate (ORR) and secondary objectives included progression-free survival (PFS) and safety.
  • 199 patients enrolled in 31 IFM centers with a median age of 73.2 years
  • 65.8% achieved ORR and 53.3% reached very good partial response (VGPR) or better
  • At 10 months, estimated PFS was 56% and overall survival (OS) was 68.5%
  • Cytokine release syndrome occurred in 33.2% of patients, without grade >2 cases.

Cite This Study

Hulin et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d15bhttps://doi.org/10.1182/blood-2025-5836
View Full Paper
Ask AI
Bookmark
Share